Barclays Downgrades Biomea Fusion Inc. (BMEA) to Equalweight

Barclays analyst Peter Lawson downgraded Biomea Fusion Inc. (NASDAQ: BMEA) from Overweight to Equalweight with a price target of $5.00 (from $30.00).

The analyst comments: "Following the announced clinical hold on BMF-219 in diabetes, and out of an abundance of caution, we decrease PT to $5, and downgrading to EW. The hold was triggered by possible drug induced hepatotoxicity observed in the dose escalation phase of the type 2 diabetes trial."

For an analyst ratings summary and ratings history on Biomea Fusion Inc. click here. For more ratings news on Biomea Fusion Inc. click here.

Shares of Biomea Fusion Inc. closed at $11.27 yesterday.

You May Also Be Interested In

• Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
• Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)